AKTS Aktis Oncology, Inc. - Fundamental Analysis
BEARISH
Sign in to save
Save this symbol to a watchlist or track a position.
AKTS Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Biotechnology
Current Price
Live
$18.99
Analyst Target
$31.25
+64.6%
Upside
52W High
$29.16
52W Low
$16.8
At a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
85%
Analysis Accuracy
AKTS exhibits weak financial health per the Piotroski F-Score of 3/9, indicating significant operational and profitability concerns. The company reports negative profitability metrics across all key measures, including a -1675.78% operating margin and negative ROE/ROA, with no meaningful revenue or earnings growth. Despite a strong analyst consensus of 'strong_buy' and a target price of $31.25, the stock trades at an extreme Price/Sales of 188.43 and lacks a Graham Number or intrinsic value, suggesting a speculative valuation. The absence of an Altman Z-Score and the company's negative cash flow and high debt-to-equity risk profile further compound the caution. Insider activity remains neutral, offering no conviction signal.
Key Strengths
Analyst consensus is strongly bullish with a $31.25 target price
Recent quarter showed strong Q/Q EPS growth (+94.7%) and YoY EPS growth (+85.2%)
Low debt-to-equity ratio (0.05) indicates conservative capital structure
High current and quick ratios (9.27 and 9.18) suggest strong short-term liquidity
Insider sentiment is moderately positive at 60/100, indicating some internal confidence
Key Risks
Piotroski F-Score of 3/9 signals weak financial health and operational instability
Negative operating margin (-1675.78%) and zero profit margins indicate severe profitability issues
No positive cash flow or earnings history, with forward P/E of -11.02 and negative Price/Book
Extreme Price/Sales ratio of 188.43 suggests overvaluation relative to revenue
No dividend, no earnings, and no intrinsic value or Graham Number make valuation highly speculative
Performance Snowflake
Multi-dimensional AI analysis across 5 key categories
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Historical Performance Trends
Long-term financial metrics and growth patterns
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability, Growth & Financial Health
Detailed profit margins, ROE, debt ratios, and liquidity metrics
Sector Comparison & Peer Analysis
Compare AKTS against industry averages and similar companies
Insider Trading & Analyst Ratings
Track insider transactions and Wall Street analyst recommendations
Past News Coverage
Recent headlines mentioning AKTS from our newsroom.
Newest → oldest
No matching news yet.